Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach;Raynaud-phänomen in der dermatologie. Teil 1: Pathophysiologie und diagnostik

Hautarzt

Volumn 57, Issue 9, 2006, Pages 819-830

  Sunderkotter C ^a   Riemekasten, G ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Capillarosopy; Endothelin; Raynaud phenomenon; Scleroderma; Vascular damage

Indexed keywords

ALPHA INTERFERON; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA INTERFERON; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ENDOTHELIN; ERGOTAMINE; PROSTAGLANDIN; SUMATRIPTAN; VINBLASTINE;

CLINICAL FEATURE; COLD STRESS; CYANOSIS; DIFFERENTIAL DIAGNOSIS; EMOTIONAL STRESS; ERYTHROMELALGIA; HEMATOMA; HUMAN; HYPEREMIA; PALLOR; PATHOPHYSIOLOGY; PREVALENCE; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS; VASCULAR SMOOTH MUSCLE;

HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 33748654975     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1192-x     Document Type: Review

References (33)

1. Bailey SR, Eid AH, Mitra S et al. (2004) Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 94: 1367-1374
2. Block JA, Sequeira W (2001) Raynaud's phenomenon. Lancet 357: 2042-2048
3. Boin F, Wigley FM (2005) Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 17: 752-760
4. Bukhari M, Herrick AL, Moore T et al. (1996) Increased nailfold capillary dimensions in primary Raynaud's phenomenon and systemic sclerosis. Br J Rheumatol 35: 1127-1131
5. Bunker CB, Terenghi G, Springall DR et al. (1990) Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 336: 1530-1533
6. Chotani MA, Flavahan S, Mitra S et al. (2000) Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 278: H1075-1083
7. Coffman JD, Rasmussen HM (1985) Effects of beta-adrenoreceptor-blocking drugs in patients with Raynaud's phenomenon. Circulation 72: 466-470
8. Flavahan NA, Flavahan S, Liu Q et al. (2000) Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 43: 1886-1890
9. Furspan PB, Chatterjee S, Freedman RR (2004) Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 50: 1578-1585
10. Furspan PB, Chatterjee S, Mayes MD, Freedman RR (2005) Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon. Rheumatology (Oxford) 44: 488-494
11. Herrick AL (2005) Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 44: 587-596
12. Hummers LK, Wigley FM (2003) Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma. Rheum Dis Clin North Am 29: 293-313
13. Kahaleh MB (2004) Vascular involvement in systemic sclerosis (SSc). Clin Exp Rheumatol 22: S19-23
14. Kawaguchi Y, Takagi K, Hara M et al. (2004) Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 50: 216-226
15. Knock GA, Terenghi G, Bunker CB et al. (1993) Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 101: 73-78
16. Landry GJ, Edwards JM, McLafferty RB et al. (1996) Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort. J Vasc Surg 23: 76-85; discussion 85-76
17. LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675-694
18. Maricq HR, Carpentier PH, Weinrich MC et al. (1993) Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol 20: 70-76
19. Prescott RJ, Freemont AJ, Jones CJ et al. (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166: 255-263
20. Rajagopalan S, Pfenninger D, Kehrer C et al. (2003) Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum 48: 1992-2000
21. Rajkumar VS, Sundberg C, Abraham DJ et al. (1999) Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 42: 930-941
22. Riemekasten G, Sunderkötter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) (in press)
23. Rodnan GP, Myerowitz RL, Justh GO (1980) Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 59: 393-408
24. Sarkozi J, Bookman AA, Lee P et al. (1987) Significance of anticentromere antibody in idiopathic Raynaud's syndrome. Am J Med 83: 893-898
25. Sgonc R, Gruschwitz MS, Dietrich H et al. (1996) Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 98: 785-792
26. Smyth AE, Bell AL, Bruce IN et al. (2000) Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon. Ann Rheum Dis 59: 870-874
27. Spencer-Green G (1998) Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 158: 595-600
28. Sunderkötter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology (Oxford) (in press)
29. Sunderkötter C, Seeliger S, Schonlau F et al. (2001) Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol 10: 391-404
30. ter Borg EJ, Piersma-Wichers G, Smit AJ et al. (1994) Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma. Semin Arthritis Rheum 24: 40-47
31. Waxman SG, Dib-Hajj SD (2005) Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 57: 785-788
32. Wise RA, Wigley FM, White B et al. (2004) Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from coldinduced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 50: 3994-4001
33. Yamamoto T, Nishioka K (2005) Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol 14: 81-95